Filing Details Immunovant, Inc. (NASDAQ:IMVT) filed a definitive proxy statement (DEF 14A) with the Securities and Exchange Commission on July 22, 2026. The Healthcare company's…
Immunovant, Inc. (NASDAQ:IMVT) filed a definitive proxy statement (DEF 14A) with the Securities and Exchange Commission on July 22, 2026.
The Healthcare company's proxy statement provides information for shareholders ahead of the annual meeting, including board nominations, executive compensation, and proposals for shareholder vote.
Immunovant, Inc.'s stock currently trades at $39.05 with a market capitalization of $4.4B.
SEC filings provide mandatory disclosures that give investors access to the same material information available to institutional investors. Reviewing Immunovant, Inc.'s filings alongside price action and analyst commentary provides a more complete picture of the company's current situation.
All SEC filings for Immunovant, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View IMVT Stock Page
Browse all filings on our IMVT SEC filings page.
Public companies like Immunovant, Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.
Current market data
NASDAQ · IMVT
$38.75
Down: -$0.65 · -1.68%
Live quote updated
Keep reading
